ATE356608T1 - Behandlung der multiplen sklerose durch einnahme von copolymer-1 - Google Patents

Behandlung der multiplen sklerose durch einnahme von copolymer-1

Info

Publication number
ATE356608T1
ATE356608T1 AT98901745T AT98901745T ATE356608T1 AT E356608 T1 ATE356608 T1 AT E356608T1 AT 98901745 T AT98901745 T AT 98901745T AT 98901745 T AT98901745 T AT 98901745T AT E356608 T1 ATE356608 T1 AT E356608T1
Authority
AT
Austria
Prior art keywords
treatment
multiple sclerosis
copolymer
taking
taking copolymer
Prior art date
Application number
AT98901745T
Other languages
English (en)
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE356608T1 publication Critical patent/ATE356608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
AT98901745T 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1 ATE356608T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE356608T1 true ATE356608T1 (de) 2007-04-15

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901745T ATE356608T1 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1

Country Status (18)

Country Link
EP (1) EP0975351B1 (de)
JP (1) JP4216342B2 (de)
KR (1) KR20000070058A (de)
CN (1) CN100528222C (de)
AT (1) ATE356608T1 (de)
AU (1) AU737287B2 (de)
BR (1) BRPI9807076B8 (de)
CA (1) CA2277365C (de)
CZ (1) CZ297983B6 (de)
DE (1) DE69837324T2 (de)
EA (1) EA003128B1 (de)
HU (1) HU226612B1 (de)
IL (2) IL119989A0 (de)
NZ (1) NZ336690A (de)
PL (1) PL193300B1 (de)
SK (1) SK284029B6 (de)
WO (1) WO1998030227A1 (de)
ZA (1) ZA98214B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2336238A1 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ATE287713T1 (de) * 1999-06-04 2005-02-15 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
EP1261361B1 (de) * 2000-02-18 2006-06-14 Yeda Research And Development Company, Ltd. Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
US7576101B2 (en) * 2003-01-24 2009-08-18 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
ES2572811T3 (es) 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2627669T3 (pl) 2010-10-11 2017-02-28 Teva Pharmaceutical Industries Ltd. Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
EP2765857A4 (de) 2011-10-10 2015-12-09 Teva Pharma Einzelnukleotidpolymorphismen zur vorhersage des klinischen ansprechens auf glatirameracetat
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649538B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
JP4216342B2 (ja) 2009-01-28
HUP0001917A3 (en) 2001-12-28
EP0975351B1 (de) 2007-03-14
SK93199A3 (en) 2000-11-07
NZ336690A (en) 2001-05-25
KR20000070058A (ko) 2000-11-25
BR9807076A (pt) 2000-05-02
AU5819598A (en) 1998-08-03
EP0975351A4 (de) 2002-05-15
AU737287B2 (en) 2001-08-16
IL119989A0 (en) 1997-04-15
ZA98214B (en) 1999-08-11
JP2001511121A (ja) 2001-08-07
EA003128B1 (ru) 2003-02-27
BRPI9807076B8 (pt) 2021-05-25
EP0975351A1 (de) 2000-02-02
DE69837324D1 (de) 2007-04-26
CZ297983B6 (cs) 2007-05-16
IL130820A (en) 2007-03-08
HUP0001917A2 (hu) 2000-10-28
DE69837324T2 (de) 2007-11-29
HU226612B1 (en) 2009-04-28
CZ243799A3 (cs) 2000-06-14
CN1249690A (zh) 2000-04-05
BR9807076B1 (pt) 2013-10-29
WO1998030227A1 (en) 1998-07-16
PL334566A1 (en) 2000-03-13
SK284029B6 (sk) 2004-08-03
HK1025737A1 (en) 2000-11-24
EA199900621A1 (ru) 2000-02-28
PL193300B1 (pl) 2007-01-31
CA2277365C (en) 2011-04-12
CN100528222C (zh) 2009-08-19
CA2277365A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
ATE356608T1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DE69326250D1 (de) Neuropeptide y antagoniste
DE69533264D1 (de) Inhibitoren der il-6 aktivitaet
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
EA199900239A1 (ru) Замещенные n-[аминоиминометил или аминометил) фенил] пропиламиды
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
NO974147D0 (no) Heterocykelkarbonyl aminosyre hydroksyetylamino sulfonamid retroviral protease
KR960006915A (ko) 췌장염의 치료 조성물
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
DE69820053D1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
BG103632A (en) Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment
DE60035996D1 (de) Diätetisches kalzium als ergänzung zu vitamin d verbindungen bei der behandlung von multipler sklerose
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DK0977871T3 (da) Neurotrypsin
DE60113664D1 (de) Zusammensetzung zur behandlung von herzinsuffizienz
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
DE59303446D1 (de) Neue bis-phenyl-hexene
DK0539465T3 (da) Anvendelse af 20(R)-22-oxa-D-vitamin-analoger til fremstilling af et farmaceutisk præparat til behandling og/eller forebyggelse af hudaldring
ATE276272T1 (de) Entzündungshemmende peptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties